[Phase I study of biweekly @entity1311 and @entity3003 administration in XXXX with advanced @entity1149 ].

@entity1 @entity137 @entity1261 @entity3003 @entity1149 @entity1311 @entity20756 @entity344 @entity1398
A phase I study of a biweekly outpatient regimen composed of @entity3003 ( @entity3003 ) and @entity1311 ( @entity20756 ) was conducted for advanced @entity1149 . @entity20756 was given in combination with a fixed dose of @entity3003 (AUC 3) every 2 weeks. The starting dose of @entity20756 was 100 mg/m2, and the dose was escalated in increments of 20 mg/m2. Three to six @entity1 were allocated to each level. @entity137 were evaluated in the first 4 courses to determine the maximum tolerated dose (MTD). @entity20756 160 mg/m2 dosages proved to be MTD, and the dose limiting @entity137 (DLT) was hematotoxicity ( @entity1398 ). The @entity1 , however, recovered from @entity1398 using @entity1261 immediately, when @entity1261 was used. @entity344 was well-tolerated. A response was found in 9 out of 20 @entity1 who received 4 courses or more (45%). These results suggest that the recommended dose would be @entity3003 (AUC 3) + @entity20756 140 mg/m2. The biweekly regimen has a high level clinical activity and excellent tolerability, and is suitable for outpatients. We started a phase II study because of these results.
